Only in Titles

Search results for: anti Alanine Transaminase

paperclip

Error loading info... Pleas try again later.
paperclip

#35739966   2022/05/27 To Up

Alanyl-Glutamine Protects against Lipopolysaccharide-Induced Liver Injury in Mice via Alleviating Oxidative Stress, Inhibiting Inflammation, and Regulating Autophagy.

Acute liver injury is a worldwide problem with a high rate of morbidity and mortality, and effective pharmacological therapies are still urgently needed. Alanyl-glutamine (Ala-Gln), a dipeptide formed from L-alanine and L-glutamine, is known as a protective compound that is involved in various tissue injuries, but there are limited reports regarding the effects of Ala-Gln in acute liver injury. This present study aimed to investigate the protective effects of Ala-Gln in lipopolysaccharide (LPS)-induced acute liver injury in mice, with a focus on inflammatory responses and oxidative stress. The acute liver injury induced using LPS (50 μg/kg) and D-galactosamine (D-Gal) (400 mg/kg) stimulation in mice was significantly attenuated after Ala-Gln treatment (500 and 1500 mg/kg), as evidenced by reduced plasma alanine transaminase (ALT) ( < 0.01, < 0.001), aspartate transaminase (AST) ( < 0.05, < 0.001), and lactate dehydrogenase (LDH) ( < 0.01, < 0.001) levels, and accompanied by improved histopathological changes. In addition, LPS/D-Gal-induced hepatic apoptosis was also alleviated by Ala-Gln administration, as shown by a greatly decreased ratio of TUNEL-positive hepatocytes, from approximately 10% to 2%, and markedly reduced protein levels of cleaved caspase-3 ( < 0.05, < 0.001) in liver. Moreover, we found that LPS/D-Gal-triggered oxidative stress was suppressed after Ala-Gln treatment, the effect of which might be dependent on the elevation of SOD and GPX activities, and on GSH levels in liver. Interestingly, we observed that Ala-Gln clearly inhibited LPS/D-Gal exposure-induced macrophage accumulation and the production of proinflammatory factors in the liver. Furthermore, Ala-Gln greatly regulated autophagy in the liver in LPS/D-Gal-treated mice. Using RAW264.7 cells, we confirmed the anti-inflammatory role of Ala-Gln-targeting macrophages.
Jiaji Hu, Hanglu Ying, Yigang Zheng, Huabin Ma, Long Li, Yufen Zhao

2821 related Products with: Alanyl-Glutamine Protects against Lipopolysaccharide-Induced Liver Injury in Mice via Alleviating Oxidative Stress, Inhibiting Inflammation, and Regulating Autophagy.

N/A 16-22 Sample Kit16 Arrays/Slide96T 100 UG2 Pieces/Box

Related Pathways

paperclip

#35730199   // To Up

NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance.

The study aims to detect the expression of Na/taurocholate cotransporter polypeptide in hilar cholangiocarcinoma of rat model, to provide a new therapeutic target for gene therapy of hilar cholangiocarcinoma. 60 male Wistar rats (weighing 190 ± 8 g) were randomly divided into 3 groups (experimental group, control group, and sham operation group; 20 rats in each group). The 3 groups were fed with standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a micro syringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. Comprehensive behavior score and Basso Beattie Bresnahan were used to evaluate the mental state and exercise of rats every day. At 5 weeks, one rat in the experimental group was killed, and the changes in hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumor, and hilar bile duct tissues were taken from the 3 groups. Na/taurocholate cotransporter polypeptide expression in hilar bile duct was detected by real-time polymerase chain reaction and immunohistochemistry. After 2 weeks, the rats in experimental group ate less, and their weight was significantly reduced compared with the other 2 groups. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other 2 groups. The ratio of Na/taurocholate cotransporter polypeptide/GAPDH mRNA in hilar cholangiocarcinoma, control group, and sham operation group was significantly different. Under the light microscope, Na/taurocholate cotransporter polypeptide protein reacted with anti-Na/taurocholate cotransporter polypeptide antibody and showed granular expression. Every pathological section included 4800 cells. 3823 positive cells were in the experimental group, 1765 positive cells were in the control group, and 1823 positive cells were in the sham operation group. Na/taurocholate cotransporter polypeptide expression in hilar cholangiocarcinoma of rats was significantly higher than normal hilar bile duct tissues, suggesting that drugs targeting Na/taurocholate cotransporter polypeptide may be a new strategy for the treatment of hilar cholangiocarcinoma.
Meng-Yu Zhang, Ming Luo, Kai He, Xian-Ming Xia, Jie-Ping Wang

1380 related Products with: NTCP Change in Rats of Hilar Cholangiocarcinoma and Therapeutic Significance.

900 tests100 assays1 mg 1 G250ul

Related Pathways

paperclip

#35723590   2022/06/20 To Up

Relevance of Gene Polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.

The recommended treatment regimen for tuberculosis is a combination of agents with antitubercular activity, during which hepatotoxicity is one of the most common side effects. In addition to the -acetyltransferase 2 () genotype, in nuclear receptor subfamily 1, group I, member 2 () has been demonstrated to be associated with anti-tuberculosis drug-induced hepatotoxicity (ATDH), but previous results have been inconsistent.A retrospective nested hospital-based case-control study was performed to investigate the association between genetic polymorphisms and the risk of ATDH. Fifteen genetic variants (13 SNPs and two null genotypes) in cytochrome P450 2E1, , UDP-glucuronosyltransferase 1A1, , superoxide dismutase 1, superoxide dismutase 2, and glutathione -transferases (, , were genotyped. Odds ratios with 95% confidence intervals were calculated with drug doses, body mass index comorbidity of diabetes mellitus, and baseline alanine transaminase value as covariates.Conditional logistic regression demonstrated that the slow acetylation genotype and the allele of in may contribute to susceptibility to ATDH.Stratified association analysis demonstrated that in non-slow acetylators, the allele of was a risk factor for ATDH, whereas the allele did not increase the susceptibility to ATDH in slow acetylators.
Ning Wang, Shaochen Guo, Haiting Liu, Yangming Ding, Rong Yao, Zhongquan Liu, Hui Zhu, Xi Chen, Xinting Yang, Xiaoyou Chen, Yu Lu

1616 related Products with: Relevance of Gene Polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.

100 ul100ug1 mL100ul100ug Lyophilized1 ml1 mL100 0.1 mg100 0.1 mg1 mg

Related Pathways

paperclip

#35703948   2021/11/24 To Up

Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children.

Anti-neutrophil cytoplasmic antibody (ANCA) directed against proteinase 3 (PR3) is a marker for granulomatosis with polyangiitis, but is also found in patients with inflammatory bowel disease (IBD), mainly ulcerative colitis (UC). The aim of our study was to investigate ANCA and PR3-ANCA in paediatric IBD.
Martin Walter Laass, Josefine Ziesmann, Jan de Laffolie, Nadja Röber, Karsten Conrad

2248 related Products with: Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children.

100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg100 μg

Related Pathways

paperclip

#35701526   2022/06/14 To Up

Phytochemical profiling and anti-fibrotic activities of Plumbago indica L. and Plumbago auriculata Lam. in thioacetamide-induced liver fibrosis in rats.

This study aimed at investigating the chemical composition and the hepatoprotective activities of Plumbago indica L. and P. auriculata Lam. LC-MS/MS analyses for the hydroalcoholic extracts of the aerial parts of the two Plumbago species allowed the tentative identification of thirty and twenty-five compounds from P. indica and P. auriculata, respectively. The biochemical and histopathological alterations associated with thioacetamide (TAA)-induced liver fibrosis in rats were evaluated in vivo where rats received the two extracts at three different dose levels (100, 200 and 400 mg/kg p.o, daily) for 15 consecutive days with induction of hepatotoxicity by TAA (200 mg/kg/day, i.p.) at 14th and 15th days. Results of the present study showed a significant restoration in liver function biomarkers viz. alanine transaminase (ALT), aspartate transaminase (AST), gamma glutamyl transferase and total bilirubin. The liver homogenates exhibited increased levels of antioxidant biomarkers: reduced glutathione (GSH) and catalase (CAT), accompanied with decline in malondialdehyde (MDA). Furthermore, treated groups exhibited a significant suppression in liver inflammatory cytokines: tumor necrosis factor-α (TNF-α) and interlukin-6 (IL-6), and fibrotic biomarker: alpha smooth muscle relaxant. Histopathological examination of the liver showed normality of hepatocytes. Noteworthy, P. indica extract showed better hepatoprotective activity than P. auriculata, particularly at 200 mg/kg. To sum up, all these results indicated the hepatoprotective properties of both extracts, as well as their antifibrotic effect was evidenced by reduction in hepatic collagen deposition. However, additional experiments are required to isolate their individual secondary metabolites, assess the toxicity of the extracts and explore the involved mechanism of action.
Nabil Mohamed Selim, Mina Michael Melk, Farouk Rasmy Melek, Dalia Osama Saleh, Mansour Sobeh, Seham S El-Hawary

1745 related Products with: Phytochemical profiling and anti-fibrotic activities of Plumbago indica L. and Plumbago auriculata Lam. in thioacetamide-induced liver fibrosis in rats.

50 ul100 ul100 ul50 ul100ug

Related Pathways

paperclip

#35698845   2022/06/14 To Up

Attenuation of methotrexate induced hepatotoxicity by epigallocatechin 3-gallate.

Methotrexate (MTX) is currently used as first-line therapy for autoimmune diseases like rheumatoid arthritis, psoriasis, and systemic lupus erythematous. However, its use is limited by its hepatotoxic potential. Epigallocatechin-3-gallate (EGCG), an abundant catechin present in tea possesses potent antioxidant activity and effectively ameliorates oxidative stress-related disorders. This study aimed to investigate the hepatoprotective influence of EGCG in a MTX-induced rat model of hepatotoxicity. Sprague Dawley rats pretreated with EGCG (40 mg kg b.w., p.o.) were administered a single dose of MTX (20 mg kg b.w., i.p.) and its hepatoprotective efficacy compared with folic acid (1 mg kg b.w., i.p.). On day 10, blood samples were collected to determine plasma levels of aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH), while the livers were examined for histopathogical changes along with levels of oxidative stress measured in terms of myeloperoxidase (MPO) activity, protein carbonylation (PCO), lipid peroxidation (LPO), and activities of cellular enzymatic antioxidants - superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). MTX significantly increased the plasma levels of AST, ALT, ALP, and LDH, which were prevented by pretreatment with EGCG, and was corroborated by histopathology. Additionally, MTX-induced hepatic oxidative stress as measured by increased generation of MPO, enhanced PCO, LPO, and decreased activities of antioxidant enzymes was mitigated by pretreatment with EGCG. The amelioration of MTX-induced hepatotoxicity by EGCG endorsed the inclusion of an anti-oxidant during chronic administration of MTX.
Ayan Pradhan, Shilpa Sengupta, Ritika Sengupta, Mitali Chatterjee

2906 related Products with: Attenuation of methotrexate induced hepatotoxicity by epigallocatechin 3-gallate.

50 ul100ug1 mg 100ul96 assays5ug2ug 5 G100 ul400 ug 500 G100 ul

Related Pathways

paperclip

#35697192   2022/06/11 To Up

Flavonoid and chromone-rich extract from Euscaphis Konishii Hayata leaf attenuated alcoholic liver injury in mice.

Euscaphis konishii Hayata is a traditional medicinal plant in China, and its leaves are usually used to make dishes for hepatic or gastrointestinal issues by Chinese She nationality. Pharmacological analysis showed that E. konishii leaves contain high levels of flavonoids and chromones with favorable anti-hepatoma effect.
Wei Huang, Wan-Yi Liu, Lu-Yao Chen, Lin Ni, Xiao-Xing Zou, Min Ye, Zhong-Yi Zhang, Shuang-Quan Zou

1390 related Products with: Flavonoid and chromone-rich extract from Euscaphis Konishii Hayata leaf attenuated alcoholic liver injury in mice.

96 wells

Related Pathways

    No related Items
paperclip

#35696167   2022/06/01 To Up

Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B.

Coexistence of hepatitis B surface antigen (HBsAg) and antibody against HBsAg (anti-HBs) constitutes an atypical serological profile in chronic hepatitis B virus infection, and the association between coexistent HBsAg and anti-HBs with severe liver fibrosis and cirrhosis in patients with chronic hepatitis B (CHB) remains unclear.
Jian Wang, Weimao Ding, Jiacheng Liu, Yong Liu, Xiaomin Yan, Juan Xia, Weihua Wu, Bei Jia, Yuxin Chen, Dongmei Gao, Shuqin Hong, Xiaohong Wang, Li Wang, Xin Tong, Shengxia Yin, Zhaoping Zhang, Jie Li, Rui Huang, Chao Wu

2127 related Products with: Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis B.

100 μg100μg100ug100ug Lyophilized96T100ug100ug96T1 mg1 ml96T100ug Lyophilized

Related Pathways

paperclip

#35692470   2022/01/31 To Up

Co-administration of chloroquine and coenzyme Q improved treatment outcome during experimental cerebral malaria.

Development of cerebral malaria (CM) is driven by parasitemia levels, harmful inflammatory response, oxidative stress and consequent breach of the blood brain barrier. Use of adjunct therapy that utilizes an antioxidant and anti-inflammatory agent alongside chloroquine (CQ), may improve treatment outcome and shorten recovery from post-infection sequelae. Though withdrawn in some countries, CQ is still in use for prophylaxis and treatment of malaria in many countries. Current study investigated whether oral co-administration of 50 mg/kg CQ and 200 mg/kg of coenzyme Q (CoQ) would improve treatment outcome against experimental cerebral malaria (ECM) and assuage the deleterious effects of oxidative stress and inflammation upon infection by ANKA (PbA) in a C57BL/6 J mouse model. Treatment with CQ + CoQ resulted in an improved parasite elimination; clearing the parasite one day early, when compared to mice on CQ alone. Remarkably, treatment with CQ and CoQ separately or in combination, assuaged PbA induced elevation of serum levels of TNF-α and IFN-γ an indication of protection from ECM progression. Furthermore, CQ and CoQ-administration, blocked parasite-driven elevation of aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin. In the presence of CQ and CoQ severe PbA-induced systemic induction of oxidative stress and resultant GSH depletion was reduced in the brain, liver, spleen, and kidney. Overall, these findings demonstrate that administration of CQ and CoQ ameliorates harmful parasite-driven oxidative stress and inflammation, while slowing the progression to full blown ECM and may improve treatment outcome in CM.
David B Ouko, Peris W Amwayi, Lucy A Ochola, Peninah M Wairagu, Alfred Orina Isaac, James N Nyariki

1688 related Products with: Co-administration of chloroquine and coenzyme Q improved treatment outcome during experimental cerebral malaria.

200 Tests 100 G1001 kit5x50 ug1 mg20 ul1 mg 1 G10 mg100 assays

Related Pathways